References
- GridelliCde MarinisFCappuzzoFTreatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian association of thoracic oncologyClin Lung Cancer201415317318124486058
- WoodKHensingTMalikRSalgiaRPrognostic and predictive value in KRAS in non-small-cell lung cancer: a reviewJAMA Oncol20162680581227100819
- HicklinDJEllisLMRole of the vascular endothelial growth factor pathway in tumor growth and angiogenesisJ Clin Oncol20052351011102715585754
- GoelHLMercurioAMVEGF targets the tumour cellNat Rev Cancer2013131287188224263190
- SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
- GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
- LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952
- HuXZhangJXuBMulticenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancerInt J Cancer201413581961196924604288
- SongZYuXLouGShiXZhangYSalvage treatment with apatinib for advanced non-small-cell lung cancerOnco Targets Ther2017101821182528367065
- DingLLiQJYouKYJiangZMYaoHRThe use of apatinib in treating non-small-cell lung cancer: case report and review of literatureMedicine (Baltimore)20169520e359827196461
- FangSCZhangHTZhangYMXieWPApatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinomaOnco Targets Ther20171044745228176910